Risk of Pancreatic Cancer in Families with Lynch Syndrome Defined(11/3/2009) Researchers from several U.S. medical centers have reported that patients with Lynch syndrome have an 8.6-fold increase in the risk of pancreatic cancer compared with the general population. The details of this study appeared in the October 28, 2009 issue of the Journal of the American Medical Association.
Smoking Increases Risk of Pancreatic Cancer(8/26/2009) Researchers from the National Cancer Institute have reported that smoking increases the risk of developing pancreatic cancer and that smoking cessation lowers this risk to baseline in 15 years. The details of this study appeared in the August 15, 2009 issue of the American Journal of Epidemiology.
Study Confirms Increased Risk of Pancreatic Cancer in A, B, or AB Individuals(8/7/2009) Researchers involved in a multicenter international trial have reported that individuals with the gene variant that results in A, B, or AB blood types appear to have a higher risk of developing pancreatic cancer than individuals with the gene variant that results in blood type O. These results were published early online in Nature Genetics on August 4, 2009.
High Dietary Animal Fat Intake Increases Risk of Developing Pancreatic Cancer(7/15/2009) Researchers from the National Institutes of Health have reported that a high intake of dietary fat of animal origin increases the risk of developing pancreatic cancer. The details of this study appeared in an early online publication in the Journal of theNational Cancer Institute on June 26, 2009.
Sutent® Improves Progression-free Survival in Patients with Well Differentiated Pancreatic Islet Cell Tumors(9/29/2009) Researchers involved in an international randomized trial have reported that Sutent® (sunitinib) prolongs progression-free survival (PFS) in patients with progressive well differentiated pancreatic islet cell tumors with an acceptable toxicity profile. The details of this study were presented at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.
Adjuvant Gemzar® Prolongs Disease-free Survival in Resected Pancreatic Cancer(9/17/2009) Researchers from Japan have reported that patients with resected pancreatic cancer who receive Gemzar® (gemcitabine) have an increased disease-free survival compared with patients randomized to a control group. The details of this study appeared in the September 2009 issue of the British Journal of Cancer.
Pancreatic Cancer Care Is Inconsistent(7/23/2009) Researchers affiliated with the Cancer Programs, American College of Surgeons have reported that the quality of care for patients with pancreatic cancer varies considerably among hospitals in the United States. The details of this study appeared in June 16, 2009 issue of the Journal of the National Cancer Institute.
Obesity Worsens Outcomes After Surgery for Pancreatic Cancer(4/2/2009) Researchers from the M. D. Anderson Cancer Center and the University of Colorado have reported that pancreatic cancer patients with a body mass index (BMI) greater than 35 have a greater risk of recurrence and worse survival after surgery than patients with a lower BMI. The details of this study appeared in the March, 2009 issue of the Archives of Surgery.
Neoadjuvant Radiation Improves Survival in Pancreatic Cancer(12/12/2008) Researchers from the Weill Cornell Medical College have reported that preoperative radiation nearly doubles the survival rate for patients with operable pancreatic cancer. The details of this review were published in the November 15, 2008 issue of the International Journal of Radiation Oncology Biology Physics.
Addition of Xeloda® to Gemzar® Improves Outcomes in Pancreatic Cancer(11/2/2009) Researchers affiliated with the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG) have reported that the addition of Xeloda® (capecitabine) to Gemzar® (gemcitabine) improves outcomes of patients with advanced or metastatic pancreatic cancer. The details of this study appeared early online October 26, 2009 in the Journal of Clinical Oncology.
Sutent® Improves Progression-free Survival in Patients with Well Differentiated Pancreatic Islet Cell Tumors(9/29/2009) Researchers involved in an international randomized trial have reported that Sutent® (sunitinib) prolongs progression-free survival (PFS) in patients with progressive well differentiated pancreatic islet cell tumors with an acceptable toxicity profile. The details of this study were presented at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.
Chemotherapy Better than Alternative Medicine Approach for Inoperable Pancreatic Cancer(9/15/2009) Researchers from Columbia University have reported that patients receiving Gemzar® (gemcitabine)-based chemotherapy for inoperable pancreatic cancer have a longer survival and better quality of life than those receiving an alternative medicine approach consisting of enzyme therapy, nutritional supplements, detoxification, and an organic diet. These results were published early online in the Journal of Clinical Oncologyon August 17, 2009.
The Addition of Eloxatin® to Gemzar® May Not Improve Outcomes in Pancreatic Cancer(7/27/2009) Researchers affiliated with the Eastern Cooperative Group have reported that the addition of Eloxatin® (oxaliplatin) to Gemzar® (gemcitabine) did not improve survival of patients with advanced pancreatic cancer. The same study also concluded that a fixed-dose rate of Gemzar was no better than the standard weekly administration. The details of this study appeared in an early online publication in the Journal of Clinical Oncology on July 6, 2009.
Pancreatic Cancer Care Is Inconsistent(7/23/2009) Researchers affiliated with the Cancer Programs, American College of Surgeons have reported that the quality of care for patients with pancreatic cancer varies considerably among hospitals in the United States. The details of this study appeared in June 16, 2009 issue of the Journal of the National Cancer Institute.
Pancreatic Cancer Care Is Inconsistent(7/23/2009) Researchers affiliated with the Cancer Programs, American College of Surgeons have reported that the quality of care for patients with pancreatic cancer varies considerably among hospitals in the United States. The details of this study appeared in June 16, 2009 issue of the Journal of the National Cancer Institute.
Normalization of N-telopeptide Associated with Improved Survival from Bone Metastasis Treated with Bisphosphonates(6/25/2008) Researchers involved in a multicenter international trial have reported that normalization of N-telopeptide of type I collagen (NTX) levels is associated with skeletal-related events and survival among patients with bone metastases from solid tumors treated with Zometa® (zoledronic acid) or Aredia® (pamidronate). These results were published in the July 1, 2008 issue of Cancer.
Different Chemotherapy Combinations Effective in Pancreatic Cancer(11/16/2007) A multi-center randomized trial comparing three different palliative chemotherapy regimens for patients with advanced pancreatic cancer has found that all three regimens were equally effective but with differing side effects. The details of this study appeared in an early on-line publication in the Annals of Oncology on October 24, 2007.
Gemzar® Plus Second Chemotherapy Agent Provides Small Survival Benefit in Advanced Pancreatic Cancer(10/8/2007) Researchers from France have reported that the combination of Gemzar® (gemcitabine) with a second chemotherapy agent provides a small but significant improvement in survival compared with Gemzar only in the treatment of metastatic pancreatic cancer. The details of this metaanalysis were reported in the October, 2007 issue of Drugs and Aging.
Weekly Taxol®, Eloxatin®, Leucovorin and 5-FU Promising for Metastatic Pancreatic Cancer(3/23/2007) Researchers from the Seattle Cancer Treatment and Wellness Center have reported significant and prolonged responses in 7 patients with metastatic pancreatic cancer treated with weekly Taxol (paclitaxel), Eloxatin, leucovorin, and 5-FU for 12 weeks. The details of this small phase II study were presented at the 2007 Gastrointestinal Symposium in Orlando Florida sponsored by the American Society of Clinical Oncology.
Patient Home
